Study on the Predictive Value of High-sensitivity Cardiac Troponin I, N-terminal Pro-B-natriuretic Peptide, and Soluble Suppression of Tumorigenesis-2 for Mortality and the Development of Cardiovascular Events in Patients With Type 2 Diabetes (Diabetes-CV)
RecruitingOBSERVATIONAL
Enrollment
1,002
Participants
Timeline
Start Date
April 18, 2024
Primary Completion Date
December 31, 2028
Study Completion Date
December 31, 2028
Conditions
Type 2 DiabetesCardiovascular Complication
Trial Locations (1)
60127
RECRUITING
IRCCS INRCA Hospital, Ancona
All Listed Sponsors
lead
Istituto Nazionale di Ricovero e Cura per Anziani
OTHER
NCT06902857 - Study on the Predictive Value of High-sensitivity Cardiac Troponin I, N-terminal Pro-B-natriuretic Peptide, and Soluble Suppression of Tumorigenesis-2 for Mortality and the Development of Cardiovascular Events in Patients With Type 2 Diabetes (Diabetes-CV) | Biotech Hunter | Biotech Hunter